Elena Herrera-Carrillo led a team at Amsterdam University Medical Center that used CRISPR/Cas genome editing to inactivate HIV strains in CD4 T cells. "We have developed an efficient combinatorial CRISPR-attack on [HIV] in various cells and the locations where it can be hidden in reservoirs, and demonstrated that therapeutics can be specifically delivered to the cells of interest," Herrara-Carillo and colleagues said.